Altering Post Vaccination T Cell Contraction
Altering Post Vaccination T Cell Contraction
批准号:
7425503
负责人:
DAVID J COLE
金额:
$12.64万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-11-01 至 2009-04-30
关键词:
Adoptive TransferAntigensApoptosisApoptoticApplications GrantsCD8B1 geneCancer Vaccine Related DevelopmentCancer VaccinesClinical DataCombined Modality TherapyConditionDataDevelopmentDopachrome isomeraseDoseEvaluationExposure toGelGenesGoalsImmunityInterferon Type IInterferonsInterleukin-12Interleukin-15LeadModelingMolecularMusNumbersPeptide VaccinesPeptidesPersonal SatisfactionPhasePoly I-CPositioning AttributeProcessResearchResearch PersonnelRoleSELL geneSignal TransductionSpleenSystemT-Cell ProliferationT-LymphocyteTimeTissuesTreatment EfficacyTreatment ProtocolsTumor AntigensUnited States National Institutes of HealthVaccinationVaccinesalpha-galactosylceramidebaseclinical applicationclinical efficacyconditioningcytokinedesignimmunogenicin vivoinnovationlymph nodesmelanomanovelnovel vaccinesparacrinepre-clinicalprogramsresponsetraffickingvaccine deliveryvaccine efficacy
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The molecular definition of tumor antigens has generated considerable enthusiasm for peptide-based cancer
vaccines. As clinical efficacy remains limited, the focus of our research group is peptide-based cancer vaccine
development. Using our innovative adoptive transfer model we have developed pre-clinical data for a novel
vaccine delivery system that augments the primary T cell response via sustained paracfine release of antigenic
peptide and cytokine(s). Furthermore, we have determined that post-vaccination T cell contraction is a major
response limitation. Although programmed T cell contraction has been well described, the factors that modulate
this response in the post-vaccination setting are not well defined. In this application we present preliminary data to
suggest that the presence of a danger signal, alterations in the tissue microenvironment, and cytokine
administration post-vaccination can modulate programmed T cell contraction. Given our expertise, and the
ability of our adoptive transfer model to visualize the contraction phase, we are in the unique position to further
these observations. The hypothesis of this grant proposal is that successful modulation of post-vaccination
programmed T cell contraction will lead to enhanced antitumor immunity. In this proposal, we will use
our adoptive transfer model to precisely define the mechanisms of programmed T cell contraction and the
impact of specific danger signals (alpha GalCer and poly I:C) on this process. We will characterize the role of
tissue microenvironment and altered T cell trafficking on post-vaccination T cell contraction and describe the
impact of myeloablative conditioning regimens on the same. Further, we will delineate the impact of post-
vaccination systemic cytokine administration (IL-2, IL-15, and type 1 interferon) on programmed T cell
contraction and define the impact of dose, timing of administration, and combination therapy on vaccine
efficacy. We will then validate the most efficacious of these approaches in the poorly immtmogenic TRP-2
murine melanoma model. Defining the factors that modulate programmed T cell contraction will provide
critical information required for the design of more effective peptide vaccine strategies
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
TCR Transduced CD8+ T Cells for Adoptive Immunotherapy
-
批准号:8555357
-
项目类别:
-
资助金额:$27.95万
-
财政年份:2011
-
负责人:DAVID J COLE
-
依托单位:
Clinical Trials using TCR Transduced T Cells for Adoptive Immunotherapy
-
批准号:8555361
-
项目类别:
-
资助金额:$69.33万
-
财政年份:2011
-
负责人:DAVID J COLE
-
依托单位:
CLINICAL TRIAL: ACTIVE IMMUNOTHERAPY AFTER RESECTION OF HEPATIC METASTASES OF CO
-
批准号:7719587
-
项目类别:
-
资助金额:$0.16万
-
财政年份:2008
-
负责人:DAVID J COLE
-
依托单位:
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
-
批准号:7667203
-
项目类别:
-
资助金额:$27.88万
-
财政年份:2007
-
负责人:DAVID J COLE
-
依托单位:
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
-
批准号:7894765
-
项目类别:
-
资助金额:$27.88万
-
财政年份:2007
-
负责人:DAVID J COLE
-
依托单位:
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
-
批准号:7305271
-
项目类别:
-
资助金额:$28.75万
-
财政年份:2007
-
负责人:DAVID J COLE
-
依托单位:
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
-
批准号:7497986
-
项目类别:
-
资助金额:$27.88万
-
财政年份:2007
-
负责人:DAVID J COLE
-
依托单位:
TARGETING THE CASM ONCOGENE AS A NOVEL THERAPY FOR PANCREATIC CANCER
-
批准号:8118020
-
项目类别:
-
资助金额:$27.04万
-
财政年份:2007
-
负责人:DAVID J COLE
-
依托单位:
IN VIVO EFFECTOR CELL RESPONSE TO PEPTIDE VACCINATION
-
批准号:6633528
-
项目类别:
-
资助金额:$22.52万
-
财政年份:2001
-
负责人:DAVID J COLE
-
依托单位:
IN VIVO EFFECTOR CELL RESPONSE TO PEPTIDE VACCINATION
-
批准号:6263186
-
项目类别:
-
资助金额:$22.19万
-
财政年份:2001
-
负责人:DAVID J COLE
-
依托单位:
Targeting Early Activated T cells for Adoptive Therapy
-
批准号:7729347
-
项目类别:
-
资助金额:$25.93万
-
财政年份:2001
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:7392294
-
项目类别:
-
资助金额:$24.92万
-
财政年份:2001
-
负责人:DAVID J COLE
-
依托单位:
Targeting Early Activated T cells for Adoptive Therapy
-
批准号:7876822
-
项目类别:
-
资助金额:$25.93万
-
财政年份:2001
-
负责人:DAVID J COLE
-
依托单位:
IN VIVO EFFECTOR CELL RESPONSE TO PEPTIDE VACCINATION
-
批准号:6514208
-
项目类别:
-
资助金额:$22.52万
-
财政年份:2001
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:7087944
-
项目类别:
-
资助金额:$25.66万
-
财政年份:1999
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:6913665
-
项目类别:
-
资助金额:$26.28万
-
财政年份:1999
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:7226764
-
项目类别:
-
资助金额:$24.92万
-
财政年份:1999
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:6821679
-
项目类别:
-
资助金额:$26.28万
-
财政年份:1999
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:7226938
-
项目类别:
-
资助金额:$12.58万
-
财政年份:1999
-
负责人:DAVID J COLE
-
依托单位:
Altering Post Vaccination T Cell Contraction
-
批准号:7119390
-
项目类别:
-
资助金额:$11.36万
-
财政年份:1999
-
负责人:DAVID J COLE
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: